Study #2022-0022
BETA-PRIME: An Adapted Phase 2a/2b Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 In Subjects With Refractory Solid Tumors
MD Anderson Study Status
Enrolling
Treatment Agent
AdAPT-001, Checkpoint Inhibitor, Immune
Description
AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Solid Tumor, Adult, Cancer, Neoplasms, Sarcoma, Sarcoma, Soft Tissue, Chondrosarcoma
Study phase:
Phase II
Physician name:
Anthony Conley
Department:
Sarcoma Medical Oncology
For general questions about clinical trials:
1-866-478-2259
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.